The area of IP generally, and pharmaceuticals in particular, within that chapter is a very important—and I think “sensitive” is fair—topic for everybody around that table. We are at the table pushing for, and negotiating hard for, an outcome that represents Canadian policy and the balance we have struck.
On March 25th, 2014. See this statement in context.